CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

NCT07461831 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Large B-Cell Lymphoma (LBCL)

Interventions

DRUG: CD19/CD22 bispecific CAR-T cells

Sponsor

Beijing Tongren Hospital